Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer : a structure-based in-silico approach
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Among the most prevalent forms of cancer are breast, lung, colon-rectum, and prostate cancers, and breast cancer is a major global health challenge, contributing to 2.26 million cases with approximately 685,000 deaths worldwide in 2020 alone, typically beginning in the milk ducts or lobules that produce and transport milk during lactation and it is becoming challenging to treat as the tissues are developing resistance, which makes urgent calls for new multitargeted drugs. The multitargeted drug design provides a better solution, simultaneously targeting multiple pathways, even when the drug resists one, it remains effective for others. In this study, we included four crucial proteins that perform signalling, receptor, and regulatory action, namely- NUDIX Hydrolases, Dihydrofolate Reductase, HER2/neu Kinase and EGFR and performed multitargeted molecular docking studies against human-approved drugs using HTVS, SP and extra precise algorithms and filtered the poses with MM\GBSA, suggested a benzodiazepine derivative chlordiazepoxide, used as an anxiolytic agent, can be a multitargeted inhibitor with docking and MM\GBSA score ranging from - 4.628 to - 7.877 and - 18.59 to - 135.86 kcal/mol, respectively, and the most interacted residues were 6ARG, 6GLU, 3TRP, and 3VAL. The QikProp-based ADMET and DFT computations showed the suitability and stability of the drug candidate followed by 100 ns MD simulation in water and MMGBSA on trajectories, resulting in stable performance and many intermolecular interactions to make the complexes stable, which favours that chlordiazepoxide can be a multitargeted breast cancer inhibitor. However, experimental validation is needed before its use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Medical oncology (Northwood, London, England) - 41(2024), 5 vom: 17. Apr., Seite 117 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alsaiari, Ahad Amer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
12794-10-4 |
|---|
| Anmerkungen: |
Date Completed 18.04.2024 Date Revised 18.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12032-024-02366-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371194261 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371194261 | ||
| 003 | DE-627 | ||
| 005 | 20240418233608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12032-024-02366-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM371194261 | ||
| 035 | |a (NLM)38630325 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alsaiari, Ahad Amer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer |b a structure-based in-silico approach |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2024 | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Among the most prevalent forms of cancer are breast, lung, colon-rectum, and prostate cancers, and breast cancer is a major global health challenge, contributing to 2.26 million cases with approximately 685,000 deaths worldwide in 2020 alone, typically beginning in the milk ducts or lobules that produce and transport milk during lactation and it is becoming challenging to treat as the tissues are developing resistance, which makes urgent calls for new multitargeted drugs. The multitargeted drug design provides a better solution, simultaneously targeting multiple pathways, even when the drug resists one, it remains effective for others. In this study, we included four crucial proteins that perform signalling, receptor, and regulatory action, namely- NUDIX Hydrolases, Dihydrofolate Reductase, HER2/neu Kinase and EGFR and performed multitargeted molecular docking studies against human-approved drugs using HTVS, SP and extra precise algorithms and filtered the poses with MM\GBSA, suggested a benzodiazepine derivative chlordiazepoxide, used as an anxiolytic agent, can be a multitargeted inhibitor with docking and MM\GBSA score ranging from - 4.628 to - 7.877 and - 18.59 to - 135.86 kcal/mol, respectively, and the most interacted residues were 6ARG, 6GLU, 3TRP, and 3VAL. The QikProp-based ADMET and DFT computations showed the suitability and stability of the drug candidate followed by 100 ns MD simulation in water and MMGBSA on trajectories, resulting in stable performance and many intermolecular interactions to make the complexes stable, which favours that chlordiazepoxide can be a multitargeted breast cancer inhibitor. However, experimental validation is needed before its use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Density functional theory | |
| 650 | 4 | |a MM\GBSA | |
| 650 | 4 | |a Molecular dynamics simulation | |
| 650 | 4 | |a Multitargeted drug design | |
| 650 | 7 | |a Chlordiazepoxide |2 NLM | |
| 650 | 7 | |a 6RZ6XEZ3CR |2 NLM | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 700 | 1 | |a Gharib, Amal F |e verfasserin |4 aut | |
| 700 | 1 | |a Bakhuraysah, Maha Mahfouz |e verfasserin |4 aut | |
| 700 | 1 | |a Alrehaili, Amani A |e verfasserin |4 aut | |
| 700 | 1 | |a Algethami, Shatha M |e verfasserin |4 aut | |
| 700 | 1 | |a Alsaif, Hayfa Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Al Harthi, Norah |e verfasserin |4 aut | |
| 700 | 1 | |a Hakami, Mohammed Ageeli |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical oncology (Northwood, London, England) |d 1997 |g 41(2024), 5 vom: 17. Apr., Seite 117 |w (DE-627)NLM075077132 |x 1559-131X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:5 |g day:17 |g month:04 |g pages:117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12032-024-02366-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 5 |b 17 |c 04 |h 117 | ||